Destiny Pharma Ltd., a small UK antibiotic developer, and its lead "rapidly bactericidal" product XF-73, has placed itself firmly on the radar in the US. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is sponsoring and funding a clinical trial which is expected to complete in the coming weeks. If successful, XF-73 will be filed for the prevention of post-surgical Staphylococcal infections, a completely new indication. CEO Dr Bill Love explained to Scrip why the interest in Destiny's child.
XF-73 is being developed against Staphylococcus aureus, including the multi-antibiotic resistant strain, methicillin-resistant S. aureus (MRSA).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
